Coherus Oncology, Zumutor Biologics team up on Phase 1 trial combining ZM008 with LOQTORZI

Coherus Oncology, Inc.

Coherus Oncology, Inc.

CHRS

0.00
  • Coherus Oncology entered a clinical collaboration with Zumutor Biologics to test ZM008 with LOQTORZI (toripalimab-tpzi) in Phase 1.
  • Zumutor will sponsor the U.S. study; Coherus will supply LOQTORZI under a clinical trial collaboration and supply agreement.
  • Trial NCT06451497 targets solid tumors; enrollment up to 45 patients across dose-escalation and expansion cohorts.
  • Partners retained commercial rights to their respective drugs for monotherapy use or in combinations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606231400PRIMZONEFULLFEED9751311) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.